目的 探討脈血康膠囊聯(lián)合巴曲酶治療突發(fā)性耳聾的臨床效果。方法 選取天津市泰達(dá)醫(yī)院2015年10月-2017年10月收治的突發(fā)性耳聾患者114例，隨機(jī)分為對(duì)照組（57例）和治療組（57例）。對(duì)照組靜脈滴注巴曲酶注射液，首劑量為10 BU加入100 mL生理鹽水，隔日1次，維持劑量為5 BU/次，每次給藥時(shí)間>1 h。治療組在對(duì)照組基礎(chǔ)上口服脈血康膠囊，3粒/次，3次/d。兩組均連續(xù)治療10 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者聽(tīng)力閾值、凝血-抗凝-纖溶系統(tǒng)指標(biāo)、血液流變學(xué)指標(biāo)和炎性因子水平。結(jié)果 治療后，對(duì)照組和治療組的臨床總有效率分別為77.2%和91.2%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者0.5、1、2、4 kHz的聽(tīng)力閾值較治療前均顯著下降（P<0.01），且治療后治療組聽(tīng)力閾值明顯低于對(duì)照組（P<0.01）。治療后，兩組血漿纖維蛋白原（FIB）水平和血清D-二聚體（D-D）水平均顯著下降（P<0.01），血清抗凝血酶Ⅲ（ATⅢ）水平顯著上升（P<0.01），且治療后治療組凝血-抗凝-纖溶系統(tǒng)指標(biāo)優(yōu)于對(duì)照組（P<0.01）。治療后，兩組患者紅細(xì)胞沉降率（ESR）、血漿黏度（PV）值較治療前明顯降低（P<0.05），紅細(xì)胞變形指數(shù)（EDI）值明顯增加（P<0.05），且治療后治療組血液流變學(xué)指標(biāo)明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者白細(xì)胞介素（IL）-6、腫瘤壞死因子（TNF）-α和超敏C反應(yīng)蛋白（hs-CRP）水平均顯著下降（P<0.01），且治療組上述炎性因子水平明顯低于對(duì)照組（P<0.01）。結(jié)論 脈血康膠囊聯(lián)合巴曲酶注射液治療突發(fā)性耳聾可短期內(nèi)消除患者耳周感覺(jué)異常、頭暈等癥狀，有效調(diào)節(jié)凝血-抗凝-纖溶系統(tǒng)平衡，改善血液流變學(xué)狀態(tài)，減輕炎性反應(yīng)。

Objective To investigate the clinical effect of Maixuekang Capsules combined with batroxobin in treatment of sudden deafness. Methods Patients (114 cases) with sudden deafness in Tianiin TEDA Hospital from October 2015 to October 2017 were randomly divided into control (57 cases) and treatment (57 cases) groups. Patients in the control group were iv administered with Batroxobin Injection, the initial dosage was 10 BU, and were added into normal saline 100 mL, once every 2 d, the maintenance dose was 5 BU/time, and the administration time was more than 1 h. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the hearing thresholds, the coagulant, anticoagulant and fibrinolytic system indicators, the hemorheological indexes and the inflammatory cytokines in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 77.2% and 91.2% respectively, and there were differences between two groups (P<0.05). After treatment, the hearing thresholds of 0.5, 1, 2, and 4 kHz in two groups was significantly decreased (P<0.01), and the hearing thresholds in the treatment group after treatment was significantly lower than that in the control group (P<0.01). After treatment, the FIB and D-D levels in two groups were significantly decreased (P<0.01), but the ATⅢ levels were significantly increased (P<0.01), and the coagulant, anticoagulant and fibrinolytic system indicators in the treatment group after treatment were significantly better than those in the control group (P<0.01). After treatment, the ESR and PV in two groups were significantly decreased (P<0.05), but EDI were significantly increased (P<0.05), and the hemorheological indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the IL-6, TNF-α and hs-CRP levels in two groups was significantly decreased (P<0.01), and these the inflammatory cytokines levels in the treatment group after treatment were significantly lower than that in the control group (P<0.01). Conclusion Maixuekang Capsules combined with batroxobin in treatment of sudden deafness can shortly eliminate symptoms of abnormal auricular sensation,dizziness and so on, can effectively regulate the coagulation-anticoagulant-fibrinolytic system, improve the hemorheological, reduce the inflammatory reaction.